Toragen is a San Diego biotechnology company developing, repurposing and commercializing uniquely selective drugs that target cancers caused by human papillomavirus (HPV). The company’s lead drug candidate is entering a Phase I clinical trial. Toragen plans to use proceeds from its recent financing primarily for research and development, including the Phase I trial and advancement of next-generation preclinical compounds. Management cited payroll for R&D and management teams and general corporate overhead as additional uses of funds. Toragen was founded by Andrew Sharabi, MD, PhD, an associate professor at UC San Diego; Sandra Coufal, MD, serves as CEO and Cheryl Collett as CFO. No operating metrics (revenue/users) were disclosed in the articles.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2022